MedWorm: Radioiodine Therapy

Complementary treatment of siTERT for improving the antitumor effect of TERT-specific I-131 therapy

Cancer Gene Therapy — Fri, 03 Feb 2012 05:00:00 +0100

Authors: S Kim, H Youn, M G Song, J H Kang, H K Chung, D S Lee & J-K Chung (Source: Cancer Gene Therapy)

MedWorm Sponsor Message: Find the best January Sales in the UK.

The Utility of I-123 Pretherapy Scan in I-131 Radioiodine Therapy for Thyroid Cancer

Thyroid — Thu, 02 Feb 2012 21:38:29 +0100

Thyroid , Vol. 0, No. 0. (Source: Thyroid)

Benefits of automated surface decontamination of a radioiodine ward.

Health Physics — Sun, 29 Jan 2012 07:06:21 +0100

Authors: Westcott E, Broadhurst A, Crossley S, Lee L, Phan X, Scharli R, Xu Y Abstract ABSTRACT:: A floor-washing robot has been acquired to assist physicists with decontamination of radioiodine therapy ward rooms after discharge of the patient at Sir Charles Gairdner Hospital. The effectiveness of the robot in decontaminating the ward has been evaluated. A controlled experiment was performed by deliberately contaminating a polyvinyl chloride flooring offcut with I followed by automated decontamination with the robot. The extent of fixed and removable contamination was assessed before and after decontamination by two methods: (1) direct Geiger-Mueller counting and (2) beta-counting wipe tests. Surface contamination was also assessed in situ on the ward by Geiger-Mueller counting an...

Insular thyroid cancer

Cancer — Tue, 17 Jan 2012 05:00:00 +0100

CONCLUSIONS:ITC is rare and aggressive. The current results indicated that its treatment should include total thyroidectomy and high‐dose radioiodine for all patients and neck dissections for patients with lymph node disease. Early diagnosis and close surveillance are essential in the management of patients with ITC. Cancer 2011. © 2011 American Cancer Society. (Source: Cancer)

Correlation between thyroid volume determined either by ultrasound or by scintigraphy and its implications in dosimetric radioiodine calculations in Graves disease treatment

Arquivos Brasileiros de Endocrinologia e Metabologia — Sat, 14 Jan 2012 00:35:00 +0100

CONCLUSIONS: Good correlation between both methods was observed, although scintigraphy systematically obtained greater volumes than ultrasound implying in lower estimatives of absorbed dose when scintigraphy is used. (Source: Arquivos Brasileiros de Endocrinologia e Metabologia)

Development of hypothyroidism during long‐term follow‐up of patients with toxic nodular goitre after radioiodine therapy

Clinical Endocrinology — Sat, 07 Jan 2012 02:18:45 +0100

Conclusions Radioiodine treatment with a calculated dose regimen is a highly effective treatment option in patients with toxic goitre with an overall success rate of 98%. However, radioiodine treatment with an intended thyroid dose of 150 Gy leads to a high incidence of hypothyroidism on long‐term follow‐up. This finding supports the suggestion that in future intended thyroid doses could be lowered in patients treated with a calculated dose regimen for toxic nodular goitre. (Source: Clinical Endocrinology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Changes in TNM stage, reoperation and 131‐I ablation rate during the use of newer methods for the preoperative diagnosis of differentiated thyroid carcinoma

Clinical Endocrinology — Sat, 07 Jan 2012 02:18:43 +0100

Conclusions The evaluation of thyroid nodules using the newer diagnostic methods was useful in identifying DTC early. Consequently, the reoperation and thyroid remnant ablation rates were reduced. (Source: Clinical Endocrinology)

Time course of Graves’ ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study

Endocrine — Wed, 14 Dec 2011 16:40:41 +0100

Abstract The findings in hyperthyroid patients with Graves’ orbitopathy (GO) of antibodies against antigens shared between the thyroid and orbit, such as the TSH-receptor (TRAb) and a novel protein G2s (G2sAb), suggested a possible common therapeutic strategy. However, the gold therapeutic standard for hyperthyrodism in these patients remains still unsettled and is mainly based on personal experience. Studies on the effect of total thyroidectomy (TT) alone or followed by radioiodine ablation (RAI) of thyroid remnants showed often conflicting results. This longitudinal study was aimed at evaluating the influence of TT alone or followed by post-surgical RAI with respect to methimazole treatment on the activity and severity of GO in patients with hyperthyroidism and GO. Six...

Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter

Surgery — Thu, 01 Dec 2011 05:00:00 +0100

Conclusion: GLV-1h153 is an effective oncolytic agent against ATC. The results show hNIS-specific radiouptake in infected ATC cells, facilitating deep-tissue imaging. GLV-1h153 is a promising candidate for treatment and imaging, and potentially enhancing susceptibility to radioiodine therapy by converting non–hNIS-expressing cells into hNIS-expressing ATC cells. (Source: Surgery)

Fibrinogen and D-dimers levels in patients with hyperthyroidism before and after radioiodine therapy.

Endokrynologia Polska — Sun, 20 Nov 2011 03:42:05 +0100

Conclusions: Hyperthyroidism is associated with a tendency toward hypercoagulation and hyperfibrinolysis. The changes observed in plasma fibrinogen and D-dimers levels are reversible. Fibrinogen level decreases within reference range and D-dimers level decreases almost to the upper reference range. They depend on severity and autoimmunity of the underlying thyroid disease and may be modified by restoring euthyroidism. (Pol J Endocrinol 2011; 62 (5): 409-415). PMID: 22069101 [PubMed - in process] (Source: Endokrynologia Polska)

Glitazone Pretreatment Can Boost Efficacy Of Radioiodine Therapy In Metastatic Thyroid Cancer

Health News from Medical News Today — Mon, 31 Oct 2011 09:00:00 +0100

Repeated radio-ablation therapy with iodine-131 to treat metastatic thyroid cancer can be less effective than the initial round of treatment due to de-differentiation of the cancer cells as the disease progresses, making them less sensitive to I-131. Glitazones, a class of PPARg drugs capable of re-differentiating the cancer cells, can enhance their I-131 uptake. Long-term use of these agents for treatment of diabetes has been linked to cardiovascular side effects... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Adding surgery as a complementary approach to radioiodine therapy in patients of differentiated thyroid carcinoma with large solitary flat bone metastases: the unresolved issues

Journal of Surgical Oncology — Mon, 17 Oct 2011 04:00:00 +0100

(Source: Journal of Surgical Oncology)

Carotid artery rupture following radioiodine therapy for differentiated thyroid carcinoma

Arquivos Brasileiros de Endocrinologia e Metabologia — Sat, 15 Oct 2011 07:44:00 +0100

DISCUSSION: Side effects are uncommon after radioiodine therapy and when present, have mild intensity. Serious adverse events are very rare, especially those arising from structures not directly invaded by metastatic tissue with radioiodine uptake, as occurred in this case. This occurrence serves to raise awareness of the need for increased care when using radioiodine therapy on high-avidity masses located close to important structures.INTRODUÇÃO: Iodoterapia em pacientes com carcinoma diferenciado da tireoide tem o objetivo de reduzir a recorrência tumoral erradicando focos residuais macro e microscópicos. Os efeitos colaterais, em geral, são raros, tênues e transitórios, com pouca repercussão clínica. OBJETIVO: Relatar um caso raro de carcinoma diferenciado da tireoide apresenta...

Body mass index and screening for cardiovascular disease risk

Arquivos Brasileiros de Endocrinologia e Metabologia — Sat, 15 Oct 2011 07:44:00 +0100

Response to the letter sent by Dr. Viroj Wiwanitkit entitled "Body mass index and screening for cardiovascular disease risk"

Arquivos Brasileiros de Endocrinologia e Metabologia — Sat, 15 Oct 2011 07:44:00 +0100

Image-Guided Tumor-Selective Radioiodine Therapy of Liver Cancer After Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene

Human Gene Therapy — Tue, 11 Oct 2011 19:18:33 +0100

Human Gene Therapy , Vol. 0, No. 0. (Source: Human Gene Therapy)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer

BMC Research Notes — Tue, 11 Oct 2011 04:00:00 +0100

Conclusions: Further investigation on genes associated with cell surface NIS protein levels within each breast cancer molecular subtype may lead to novel targets for selectively increasing NIS expression/function in a subset of breast cancers patients. (Source: BMC Research Notes)

Short-term effect of radioactive iodine therapy on CXCL-10 production in Graves' disease.

Clinical and Investigative Medicine — Fri, 07 Oct 2011 22:45:02 +0100

Conclusion: CXCL10 participates in the early inflammatory response after radioactive iodine therapy in patients with Graves' disease and shows a strong association with the autoimmune process. PMID: 21968267 [PubMed - in process] (Source: Clinical and Investigative Medicine)

GATE based Monte Carlo simulation of planar scintigraphy to estimate the nodular dose in radioiodine therapy for autonomous thyroid adenoma.

Zeitschrift fur Medizinische Physik — Fri, 07 Oct 2011 04:00:00 +0100

Authors: Hammes J, Pietrzyk U, Schmidt M, Schicha H, Eschner W Abstract The recommended target dose in radioiodine therapy of solitary hyperfunctioning thyroid nodules is 300-400Gy and therefore higher than in other radiotherapies. This is due to the fact that an unknown, yet significant portion of the activity is stored in extranodular areas but is neglected in the calculatory dosimetry. We investigate the feasibility of determining the ratio of nodular and extranodular activity concentrations (uptakes) from post-therapeutically acquired planar scintigrams with Monte Carlo simulations in GATE. The geometry of a gamma camera with a high energy collimator was emulated in GATE (Version 5). A geometrical thyroid-neck phantom (GP) and the ICRP reference voxel phantoms "Adult Female" (A...

Treatment of autonomously functioning thyroid nodules at a single institution: radioiodine therapy, surgery, and ethanol injection therapy

Annals of Nuclear Medicine — Wed, 05 Oct 2011 05:47:31 +0100

Conclusion Surgery is the treatment of choice for large nodules and nodules that are resistant to other treatments, because it allows prompt control of thyrotoxicosis. RI therapy is a safe and effective means of controlling thyrotoxicosis in AFTN patients. We conclude that RI therapy is the treatment of choice for definitive treatment of AFTN patients who do not have local compression symptoms. Content Type Journal ArticleCategory Original articlePages 1-6DOI 10.1007/s12149-011-0526-7Authors Yukiko Yano, Ito Hospital, 4-3-6 Jingu-mae, Shibuya, Tokyo, 150-8308 JapanKiminori Sugino, Ito Hospital, 4-3-6 Jingu-mae, Shibuya, Tokyo, 150-8308 JapanJunko Akaishi, Ito Hospital, 4-3-6 Jingu-mae, Shibuya, Tokyo, 150-8308 JapanTakashi Uruno, Ito Hospital, 4-3-6 Jingu-mae, Shib...

Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.

Medical Physics — Sat, 01 Oct 2011 04:00:00 +0100

Conclusions: The iodine uptake of salivary glands is continuously reduced during the courses of therapy. The phenomenon of hyper-radiosensitivity may to some extent account for the occurrence of salivary gland hypofunction at very low radiation doses with low dose rates in (131)I therapy. On the other hand, failure to incorporate a nonuniform and preferential uptake by salivary gland ductal cells may result in underestimating the actual dose for the critical tissue. Other methods, including (124)I voxel-based dosimetry, are warranted to further investigate the (131)I-induced salivary gland toxicity. PMID: 21992360 [PubMed - in process] (Source: Medical Physics)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Lymphocyte function following radioiodine therapy in patients with thyroid carcinoma.

Nuklearmedizin — Fri, 02 Sep 2011 04:00:00 +0100

Conclusion: Thyroid carcinoma patients receiving radioiodine therapy do not display any sign of immunosuppression. PMID: 21887454 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

REVIEW TOPIC: ENDOCRINE TUMOURS Approach to the patient with advanced differentiated thyroid cancer.

European Journal of Endocrinology — Fri, 02 Sep 2011 04:00:00 +0100

Authors: Schlumberger M, Sherman S Abstract Patients with advanced thyroid cancer may benefit from l-thyroxine treatment at doses that suppress serum TSH level, local treatment interventions and radioiodine therapy. In those patients who are refractory to radioiodine therapy and in whom progressive disease has been documented, the efficacy of cytotoxic chemotherapy is poor. Encouraging results have been obtained with the use of kinase inhibitors that should be offered as first line treatment, preferably in the context of a prospective trial. PMID: 21890651 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)

[Value of (18)F-FDG dual head coincidence imaging in predicting the efficacy of radioiodine therapy for papillary thyroid carcinoma with cervical lymph node metastasis].

Journal of Southern Medical University — Thu, 01 Sep 2011 04:00:00 +0100

CONCLUSION: (131)I-WBI is more sensitive than (18)F-FDG dual head coincidence imaging in detecting cervical LN metastasis in patients with PTC. Patients with cervical LN metastases who have positive results in both (131)I-WBI and (18)F-FDG dual head coincidence imaging tend to have a poorer response to the therapy than the patients with negative results in (18)F-FDG dual head coincidence imaging. The T/NT of the cervical LN metastases in (18)F-FDG dual head coincidence imaging is associated with the efficacy of radioiodine therapy. PMID: 21945769 [PubMed - in process] (Source: Journal of Southern Medical University)

Exhalation of 131I after radioiodine therapy: measurements in exhaled air

European Journal of Nuclear Medicine and Molecular Imaging — Wed, 17 Aug 2011 05:56:58 +0100

Conclusion The amount of exhaled radioiodine is small but by no means negligible on the first day after administration. This is the first study to provide experimental evidence on a systematic basis that radioiodine becomes exhalable in vivo, i.e. in the patient. The mechanism of organification of orally administered radioiodine remains to be investigated. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00259-011-1888-8Authors Klaus Schomäcker, Clinic of Nuclear Medicine, University of Cologne, Kerpener Straße 62, 50937 Cologne, GermanyFerdinand Sudbrock, Clinic of Nuclear Medicine, University of Cologne, Kerpener Straße 62, 50937 Cologne, GermanyThomas Fischer, Clinic of Nuclear Medicine, University of Cologne, Kerpener Straße 62, 509...

Does Radioiodine Therapy in Patients with Differentiated Thyroid Cancer Increase the Frequency of Another Malignant Neoplasm?

Infectious Diseases in Obstetrics and Gynecology — Mon, 15 Aug 2011 15:14:14 +0100

Conclusion. The frequency of another neoplasia found after 131I was similar to that found before 131I. (Source: Infectious Diseases in Obstetrics and Gynecology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

A severe haematologic adverse reaction after high dosage radioiodine therapy following blood stem cell mobilization with growth factors.

Nuklearmedizin — Mon, 15 Aug 2011 07:15:04 +0100

Authors: Freesmeyer M PMID: 21833439 [PubMed - in process] (Source: Nuklearmedizin)

Radioiodine therapy of thyroid carcinoma following Pax-8 gene transfer

Gene Therapy — Wed, 10 Aug 2011 23:00:00 +0100

Authors: D Mu, R Huang, X Ma, S Li & A Kuang (Source: Gene Therapy)

Cotransfected Sodium Iodide Symporter and Human Tyroperoxidase Genes Following Human Telomerase Reverse Transcriptase Promoter for Targeted Radioiodine Therapy of Malignant Glioma Cells

Cancer Biotherapy and Radiopharmaceuticals — Fri, 29 Jul 2011 21:28:06 +0100

Cancer Biotherapy & Radiopharmaceuticals , Vol. 0, No. 0. (Source: Cancer Biotherapy and Radiopharmaceuticals)

The Marine-Lenhart syndrome revisited.

Wiener Klinische Wochenschrift — Tue, 26 Jul 2011 23:00:00 +0100

Authors: Biersack HJ, Biermann K The coexistence of thyroid autonomy (Plummer's disease) and Graves' disease has been termed "Marine-Lenhart syndrome". During the last years, several papers have been published on the development of Graves' disease shortly after radioiodine therapy of Plummer's disease (autonomy). Especially in patients with elevated thyroid antibodies, the incidence of this event is significantly higher after radioiodine therapy of autonomy. A review of the literature dating back to 1911 is discussed in this paper. The original paper published by Marine and Lenhart comes to the conclusion that the two diseases are different expressions of one disease. Looking at the literature, we have to state now that the Marine-Lenhart syndrome has never existed: With Plummer we kno...

Graves' ophthalmopathy in patients treated with radioiodine 131-I.

Endokrynologia Polska — Tue, 12 Jul 2011 13:00:02 +0100

Conclusions: Since 5% of our Graves' disease patients developed severe GO following radioiodine treatment, an association between radioiodine therapy and severe ophthalmopathy cannot be excluded. IL-6 and IL-2 concentrations remained elevated after glucocorticoid therapy. (Pol J Endocrinol 2011; 62 (3): 214-219). PMID: 21717402 [PubMed - in process] (Source: Endokrynologia Polska)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck

European Journal of Nuclear Medicine and Molecular Imaging — Fri, 08 Jul 2011 05:49:56 +0100

Conclusion PET/MRI is superior to PET/CT in terms of tracing back a PET focus to a morphological correlate. For this reason PET/MRI enhances diagnostic certainty for lesions < 10 mm and improves pretherapeutic lesion dosimetry in DTC. Content Type Journal ArticlePages 1-7DOI 10.1007/s00259-011-1866-1Authors James Nagarajah, Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, GermanyWalter Jentzen, Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, GermanyVerena Hartung, Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, GermanySandra Rosenbaum-Kru...

Impact of flavonoids on thyroid function.

Food and Chemical Toxicology — Fri, 01 Jul 2011 23:00:00 +0100

Authors: de Souza Dos Santos MC, Gonçalves CF, Vaisman M, Ferreira AC, de Carvalho DP Flavonoids are polyphenolic compounds of natural occurrence produced by plants that are largely consumed both for therapeutic purposes and as food. Experimental data have shown that many flavonoids could inhibit thyroperoxidase activity, decreasing thyroid hormones levels thus increasing TSH and causing goiter. In humans, infants fed with soy formula have been shown to develop goiter. However, in post-menopausal women soy intake did not affect thyroid function. In thyroid tumor cell line, flavonoids were shown to inhibit cell growth, but they can also decrease radioiodine uptake, what could reduce the efficacy of radioiodine therapy. Flavonoids could also affect the availability of thyroid hormones t...

Radiochemotherapy of hepatocarcinoma via lentivirus-mediated transfer of human sodium iodide symporter gene and herpes simplex virus thymidine kinase gene.

Herpes — Thu, 30 Jun 2011 23:00:00 +0100

Authors: Chen L, Guo G, Liu T, Guo L, Zhu R Herpes simplex virus thymidine kinase (HSV-TK) gene/ganciclovir (GCV) system has been widely used as a traditional gene therapy modality, and the sodium/iodide symporter gene (NIS) has been found to be a novel therapeutic gene. Since the therapeutic effects of radioiodine therapy or prodrug chemotherapy on cancers following NIS or HSV-TK gene transfer need to be enhanced, this study was designed to investigate the feasibility of radiochemotherapy for hepatocarcinoma via coexpression of NIS gene and HSV-TK gene. PMID: 21718951 [PubMed - in process] (Source: Herpes)

Follow-up on thyroidal uptake after radioiodine therapy - how robust is the peri-therapeutic dosimetry?

Zeitschrift fur Medizinische Physik — Mon, 27 Jun 2011 23:00:00 +0100

Authors: Eschner W, Kobe C, Schicha H Radioiodine therapy (RIT) for benign thyroid diseases in Germany requires the patient to stay in a nuclear medicine therapy ward for at least 48hours and the dose to the thyroid to be computed from activity measurements performed during that stay. A major part of the total dose will be delivered after the patient's discharge from the hospital and thus has to be predicted through extrapolation with the effective half-life measured peri-therapeutically. We performed repeated thyroid uptake measurements on patients up to five months post therapy to investigate post-therapeutic changes in their effective half-lives and examine the dosimetric consequences. 12 patients (4 m, 8 f; age 36 - 76 y; 4 Graves' disease, 4 toxic adenoma, 3 toxic goitre, 1 non...

A randomized trial evaluating a block‐replacement regimen during radioiodine therapy

European Journal of Clinical Investigation — Tue, 14 Jun 2011 16:00:19 +0100

Conclusions A continuous block‐replacement regimen results in a stable thyroid function during 131I therapy but is hampered by the higher amounts of radioactivity required. The study demonstrates that the outcome in GD is highly unpredictable, while treatment failure in patients with TNG is correlated with a number of factors. (Source: European Journal of Clinical Investigation)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Radioiodine Therapy for Hyperthyroidism

New England Journal of Medicine — Wed, 18 May 2011 21:00:26 +0100

New England Journal of Medicine, Volume 364, Issue 20, Page 1978-1979, May 2011. (Source: New England Journal of Medicine)

Striving for Euthyroidism in Radioiodine Therapy of Graves' Disease: A 12-Year Prospective, Randomized, Open-Label Blinded End Point Study

Thyroid — Thu, 12 May 2011 15:26:00 +0100

Thyroid , Vol. 0, No. 0. (Source: Thyroid)

ATA Proposes Guidelines for 131I Radiation Precautions

Medscape Today Headlines — Wed, 20 Apr 2011 20:29:47 +0100

The American Thyroid Association has proposed guidelines for prevention of radiation exposure from radioiodine therapy to others and a new statement on central neck dissection for thyroid cancer. Medscape Medical News (Source: Medscape Today Headlines)

Comparison of 131I whole-body imaging, 131I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging — Wed, 20 Apr 2011 06:09:48 +0100

Conclusion Both SPECT/CT and PET/CT demonstrated high diagnostic performance in detecting metastatic thyroid cancer. SPECT/CT was highly accurate in patients who underwent a single challenge of radioiodine therapy. In contrast, 18F-FDG PET/CT presented the highest diagnostic performance in patients who underwent multiple challenges of radioiodine therapy. Content Type Journal ArticlePages 1-10DOI 10.1007/s00259-011-1809-xAuthors Jong-Ryool Oh, Department of Nuclear Medicine, Clinical Medicine Research Center, Chonnam National University Hospital, 671 Jebongno, Gwangju, 501-757 Republic of KoreaByung-Hyun Byun, Department of Nuclear Medicine, Clinical Medicine Research Center, Chonnam National University Hwasun Hospital, 160 Ilsimri, Hwasun, Jeonnam, 519-809 Republic ...

Radioiodine therapy of benign non-toxic goitre. Potential role of recombinant human TSH.

Annales d'Endocrinologie — Tue, 19 Apr 2011 23:00:00 +0100

Authors: Fast S, Bonnema SJ, Hegedüs L This review provides an update on recombinant human TSH (rh-TSH) augmented radioiodine ((131)I) therapy and outlines its potential role in the treatment of symptomatic benign multinodular non-toxic goitre. In some countries, (131)I has been used for three decades to reduce the size of nodular goitres. The feasibility of (131)I therapy depends on an adequate thyroid (131)I uptake. Based on a two-fold increase in thyroid (131)I uptake, superiority studies have convincingly demonstrated that the absorbed thyroid (131)I dose can be increased without increasing the administered (131)I activity, resulting in a 35-56% amplification of goitre reduction at one-year post radioiodine compared to conventional (without rh-TSH) (131)I therapy. Although patient...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging — Tue, 12 Apr 2011 05:50:29 +0100

Abstract Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics ...

Decrease in Dipeptidyl Peptidase IV Activity is Linked to the Efficacy of Differentiating Compounds in Follicular Thyroid Carcinoma Cell Lines

Hormone and Metabolic Research — Wed, 16 Mar 2011 00:00:00 +0100

Horm Metab ResDOI: 10.1055/s-0031-1273682AbstractMetastasized differentiated thyroid carcinoma is treated by surgery followed by radioiodine remnant ablation. The application of differentiating agents is a possibility of increasing the efficacy of radioiodine therapy. We evaluated DPP IV and aminopeptidase N, both linked to malignancy in thyroid carcinoma, and dipeptidyl peptidase II activities in human follicular thyroid carcinoma cell lines upon treatment with retinol, apicidine, and lovastatin as differentiating agents. Decrease of dipeptidyl peptidase IV (DPP IV) activity may play a role in the differentiating action. In the human cancer cell lines FTC 138 and 238, high DPP IV and low aminopeptidase N activities were recorded. Retinol treatment induced increases in thyroid-specific pro...

Radiochemotherapy of hepatocarcinoma via lentivirus–mediated transfer of human sodium iodide symporter gene and herpes simplex virus thymidine kinase gene

Nuclear Medicine and Biology — Mon, 07 Mar 2011 00:00:00 +0100

Conclusion: We demonstrate that radiochemotherapy of hepatocarcinoma via lentiviral-mediated coexpression of NIS gene and HSV-TK gene leads to stronger killing effect than single treatment, and in vivo studies are needed to verify these findings. (Source: Nuclear Medicine and Biology)

Review: Radioiodine therapy for hyperthyroidism

NeLM - News — Thu, 10 Feb 2011 00:00:00 +0100

Source: N Engl J Med Area: News This review in the New England Journal of Medicine on radioiodine therapy for hyperthyroidism begins with a case vignette followed by a discussion of the following topics and ends with the author's clinical recommendations on the management of the case in hand: . The clinical problem . Pathophysiology and the effect of therapy . Clinical evidence . Clinical use . Adverse effects . Areas of uncertainty . Guidelines from professional societies (Source: NeLM - News)

Radioiodine Therapy for Hyperthyroidism

New England Journal of Medicine — Wed, 09 Feb 2011 22:00:09 +0100

New England Journal of Medicine, Volume 364, Issue 6, Page 542-550, February 2011. (Source: New England Journal of Medicine)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Survey of Radioiodine Therapy Safety Practices Highlights the Need for User-Friendly Recommendations

Thyroid — Sat, 29 Jan 2011 23:36:52 +0100

Thyroid Feb 2011, Vol. 21, No. 2: 97-99. (Source: Thyroid)

Alternative Therapeutic Approaches in the Treatment of Primary and Secondary Dedifferentiated and Medullary Thyroid Carcinoma

Seminars in Nuclear Medicine — Fri, 28 Jan 2011 19:56:27 +0100

The prognosis of patients with surgically unresectable differentiated thyroid tumors deteriorates significantly if radioiodine therapy is or becomes ineffective, considering the limited role of conventional chemotherapies in these patients. Several alternative approaches have been investigated for the treatment of patients with advanced thyroid malignancies in recent years. Among targeted therapies, tyrosine kinase inhibitors have resulted in the most encouraging responses and could soon be, along with redifferentiation therapy, the possible palliative strategies. Radiopeptide therapy, especially with beta emitter-labeled DOTANOC, which shows a great affinity to the somatostatin receptors expressed by thyroid tumor cells, might also be an attractive approach considering its comparatively l...

The Problem of the Patient with Thyroglobulin Elevation but Negative Iodine Scintigraphy: The TENIS Syndrome

Seminars in Nuclear Medicine — Fri, 28 Jan 2011 19:56:26 +0100

The available data upon which to act in caring for patients with functioning thyroid cancer and thyroglobulin elevation/negative iodine scintigraphy (TENIS) are imperfect, almost never coming from randomized, blinded studies. When the serum thyroglobulin exceeds 2-10 ng/mL, one should use the latest imaging equipment available to find metastatic disease, especially in areas in which it is potentially resectable, ie, neck, bone, and occasionally brain, and collaborate with an experienced surgeon in removing such metastases. If one cannot locate operable metastases and/or tumor location remains elusive, empiric high-dose 131I therapy, preceded by dosimetry, should be considered. There are no randomized studies to prove that this treatment prolongs life, although there is definite evidence of...

KT5823 Differentially Modulates Sodium Iodide Symporter Expression, Activity, and Glycosylation between Thyroid and Breast Cancer Cells.

Endocrinology — Wed, 05 Jan 2011 00:00:00 +0100

In this study, we found that KT5823 does not increase but decreases iodide uptake within 0.5 h of treatment in trans-retinoic acid and hydrocortisone-treated MCF-7 breast cancer cells. Moreover, KT5823 accumulates hypoglycosylated NIS, and this effect is much more evident in breast cancer cells than thyroid cells. The hypoglycosylated NIS is core glycosylated, has not been processed through the Golgi apparatus, but is capable of trafficking to the cell surface. KT5823 impedes complex NIS glycosylation at a regulatory point similar to brefeldin A along the N-linked glycosylation pathway, rather than targeting a specific N-glycosylated site of NIS. KT5823-mediated effects on NIS activity and glycosylation are also observed in other breast cancer cells as well as human embryonic kidney cells ...

[Differentiated thyroid cancer - 2009.]

Orvosi Hetilap — Sat, 01 Jan 2011 00:00:00 +0100

Authors: Konrády A Three years ago continental guidelines were published referring management and follow-up of low risk thyroid cancer patients. The aim of this paper is to summarize the changes and new directions in this field. High risk patients require another protocol. Neck ultrasound plays important role in differential diagnosis and in detecting recurrences. Some new ultrasound techniques are discussed, too. FDG-PET can help to solve the problem of patients having negative scan and increased thyroglobulin level. In recent years there was an expansion of our knowledge about the pathomechanism of thyroid cancer. It appears that genetic alterations frequently play a key role in carcinogenesis. There are molecular methods that allow the detection of these genetic events in thyroid f...

MedWorm Sponsor Message: Find the best January Sales in the UK.

[Iodidenrichement in malignant tumours after gene transfer.]

Nuklearmedizin — Tue, 07 Dec 2010 00:00:00 +0100

Authors: Haberkorn U, Askoxylakis V, Markert A, Altmann A After the cloning of the gene encoding the sodium-iodide symporter several trials were made to develop a radioiodine treatment for multiple tumour entities based on NIS gene transfer. These studies revealed in vitro as well as in vivo a tremendous enhancement of iodide accumulation, which was followed by a rapid efflux. Therapy effects were observed in vitro by clonogenic assays and in vivo by growth inhibition of the treated tumours. However, the interpretation of these results were largely different. Problems of radioiodine therapy after NIS transfer are low efficiency of gene transfer and the short exposure time for the tumours caused by the rapid efflux. Trials to enhance therapeutic efficiency by co-transfer of the gene enc...

Clinical Significance of Observation without Repeated Radioiodine Therapy in Differentiated Thyroid Carcinoma Patients with Positive Surveillance Whole-Body Scans and Negative Thyroglobulin.

The Korean Journal of Internal Medicine — Wed, 01 Dec 2010 00:00:00 +0100

Authors: Lim DJ, O JH, Kim MH, Kim JH, Kwon HS, Kim SH, Kang MI, Cha BY, Lee KW, Son HY Currently, there is no consensus on the necessity of repeated radioiodine therapy (RAI) in patients who show iodine uptake in the thyroid bed on a diagnostic whole-body scan (DxWBS) despite undetectable thyroglobulin (Tg) levels after remnant ablation. The present study investigated the clinical outcomes of scan-positive, Tg-negative patients (WBS+Tg-) who did or did not receive additional RAI. PMID: 21179279 [PubMed - in process] (Source: The Korean Journal of Internal Medicine)

Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up

European Journal of Nuclear Medicine and Molecular Imaging — Sat, 27 Nov 2010 07:17:02 +0100

Conclusion In spite of incomplete remission of thyroid cancer at cessation of RIT, a continuing spontaneous decline of TG and clinically stable partial remissions were observed in this collective of children. Therefore, if RIT does not show further effects, the administration of further courses should be handled restrictively. Content Type Journal ArticleDOI 10.1007/s00259-010-1669-9Authors Johannes Biko, Department of Nuclear Medicine, University of Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, GermanyChristoph Reiners, Department of Nuclear Medicine, University of Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, GermanyMichael C. Kreissl, Department of Nuclear Medicine, University of Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, GermanyFred...

High Expression of the Urokinase Plasminogen Activator and Its Cognate Receptor Associates with Advanced Stages and Reduced Disease-Free Interval in Papillary Thyroid Carcinoma.

The Journal of Clinical Endocrinology and Metabolism — Wed, 24 Nov 2010 00:00:00 +0100

Conclusion: The study demonstrated that in PTC the increased gene expression of uPA and uPAR is associated with tumor invasiveness, advanced stages, and shorter DFI, suggesting their prognostic relevance. These observations warrant further investigation in larger patient populations with longer follow-up. PMID: 21106716 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review

NeLM - Disease Focused Reviews — Fri, 12 Nov 2010 00:00:00 +0100

Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: The authors concluded that radioiodine therapy for Graves' disease increased the risk of ophthalmopathy compared with antithyroid drugs. Prednisolone prophylaxis was beneficial for patients with pre-existing ophthalmopathy. This review was generally well conducted. However, a degree of caution might be required in interpreting these conclusions, given the limited amount of data available for each comparison in the review. CRD Commentary: This review's inclusion criteria were clear. Several relevant databases were searched. Efforts were made to find both published and unpublished studies without language restriction, minimising the potential for both publication and language biases. Steps were taken to minimise bias by h...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer

Head and Neck — Wed, 10 Nov 2010 00:00:00 +0100

Conclusion.These results show that patients subjected to RIT have more difficulty in draining saliva, mainly from the parotid glands, which is associated with clinical dysphagia in this subset of patients. © 2010 Wiley Periodicals, Inc. Head Neck, 2010 (Source: Head and Neck)

Radioiodine induced salivary gland dysfunction

Society for Endocrinology — Tue, 09 Nov 2010 12:00:00 +0100

Induced selective radioiodine uptake by the thyroid gland is the basis for thyroid cancer therapy. Various agents have been tested to increase radioiodine uptake in patients with deficient sodium iodide transporter (NIS). Salivary gland dysfunction is a common and serious complication of radioiodine therapy. Liu and colleagues demonstrate increased thyroidal, but not salivary gland, uptake of radioiodine in mice treated with 17-allyamino-17-demothoxygeldanamycin (17-AAG). Liu et al. (2010) Endocrine-Related Cancer accepted preprint. Read the full article at DOI: 10.1677/ERC-10-0185. (Source: Society for Endocrinology)

Radioiodine Therapy in Patients with Stage I Differentiated Thyroid Cancer

Thyroid — Sun, 07 Nov 2010 19:34:16 +0100

Thyroid , Vol. 0, No. 0. (Source: Thyroid)

Selective Embolization of Thyroid Arteries for Preresection or Palliative Treatment of Large Cervicomediastinal Goiters.

Surgical Innovation — Sun, 07 Nov 2010 00:00:00 +0100

CONCLUSION: Selective embolization of thyroid arteries can be successfully used to treat selected patients as a preoperative procedure and as an alternative to thyroid resection. Embolization can be repeated to achieve the required therapeutic aims. PMID: 21059607 [PubMed - as supplied by publisher] (Source: Surgical Innovation)

Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter

Cancer Gene Therapy — Thu, 28 Oct 2010 23:00:00 +0100

Authors: R Huang, Z Zhao, X Ma, S Li, R Gong & A Kuang (Source: Cancer Gene Therapy)

MedWorm Sponsor Message: Find the best January Sales in the UK.

[Outcomes of long-term combined treatment in follicular thyroid carcinoma].

Medicina (Kaunas) — Sun, 17 Oct 2010 02:00:04 +0100

CONCLUSION: Combined treatment (thyroidectomy + radioactive iodine treatment + hormonotherapy with thyroxine) administered to the patients with follicular thyroid carcinoma is highly effective, because overall 10-, 20-, 30-year survival was 91.2%, 81.9%, 77.1%, respectively. PMID: 20571295 [PubMed - indexed for MEDLINE] (Source: Medicina (Kaunas))

Thyroid echogenicity: A clue to precise individual dosimetry in radioiodine therapy of hyperthyroidism

Medical Hypotheses — Mon, 04 Oct 2010 00:00:00 +0100

Conclusion: Thyroid echogenicity is a probable clue to a better patient-specific dosimetry in radioiodine therapy of hyperthyroidism; direct evidences and precise estimates of benefits over current practices would be provided by controlled clinical trials. (Source: Medical Hypotheses)

The evaluation of the external dose measurement of the patients treated with radioiodine therapy

Radiation Protection Dosimetry — Tue, 21 Sep 2010 16:53:31 +0100

The aim of the study is to compare the results of the external exposure and the range of the dose spread by the patients, hospitalized in two different groups of 3–4 d receiving radioiodine therapy because of having hyperthyroidism (HT) and thyroid cancer (TC). A total of 1989 patients were evaluated retrospectively. Of the total 1517 patients had TC and 472 had HT. External exposure value was taken at hospital discharge and the distance for external measurement was 1 m at the abdominal level. External exposure values of 99.7 % patients were <30 µSv h–1 and of 0.3 %, >30 µSv h–1. The results between patient groups with TC and HT at third and fourth days, and the dissimilarity of measurement results within third and fourth days in total patients, without ...

Does the presence of regional lymph node metastases have any impact on the complete remission rate in patients with distant metastases of papillary thyroid carcinoma (PTC), treated by radioiodine therapy?

Endokrynologia Polska — Wed, 01 Sep 2010 00:00:00 +0100

Conclusions: 1. The highest percentage of complete remission was observed in patients with lymph nodes but without distant metastases (group I). 2. In the case of the presence of distant metastases there was no statistically significant difference in the percentage of complete remission between patients with or without the presence of metastases in lymph nodes. (Pol J Endocrinol 2010; 61 (5): 443-445). PMID: 21049455 [PubMed - in process] (Source: Endokrynologia Polska)

Staging of Differentiated Thyroid Carcinoma Using Diagnostic 131I SPECT/CT

American Journal of Roentgenology — Fri, 20 Aug 2010 18:02:48 +0100

CONCLUSION. Diagnostic 131I scintigraphy, planar images, and SPECT/CT complete the postsurgical staging of DTC. SPECT/CT reduces the number of equivocal diagnoses on planar imaging and improves the interpretation of 131I scintigraphy. The consequent changes in TNM scores and staging should influence the 131I dose prescribed at initial therapy. (Source: American Journal of Roentgenology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Excellent Prognosis for Patients with Solitary T1N0M0 Papillary Thyroid Carcinoma Who Underwent Thyroidectomy and Elective Lymph Node Dissection without Radioiodine Therapy: Reply to Letter

World Journal of Surgery — Tue, 20 Jul 2010 07:52:23 +0100

Content Type Journal ArticleDOI 10.1007/s00268-010-0734-7Authors Yasuhiro Ito, Kuma Hospital Department of Surgery 8-2-35, Shimoyamate-dori Chuo-ku 650-0011 Kobe JapanAkira Miyauchi, Kuma Hospital Department of Surgery 8-2-35, Shimoyamate-dori Chuo-ku 650-0011 Kobe Japan Journal World Journal of SurgeryOnline ISSN 1432-2323Print ISSN 0364-2313 (Source: World Journal of Surgery)

The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging

European Journal of Nuclear Medicine and Molecular Imaging — Tue, 13 Jul 2010 14:48:33 +0100

Conclusion The 124I PET(/CT) salivary gland dosimetry indicated that lemon juice stimulation shortly after 131I administration in radioiodine therapy increases the absorbed doses to the salivary glands. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-010-1532-zAuthors Walter Jentzen, Universität Duisburg-Essen Klinik für Nuklearmedizin Hufelandstrasse 55 45122 Essen GermanyDorothee Balschuweit, Fachhochschule Gelsenkirchen Fachbereich Physikalische Technik Gelsenkirchen GermanyJochen Schmitz, Universität Duisburg-Essen Klinik für Nuklearmedizin Hufelandstrasse 55 45122 Essen GermanyLutz Freudenberg, Universität Duisburg-Essen Klinik für Nuklearmedizin Hufelandstrasse 55 45122 Essen GermanyErnst Eising, Universität Duisburg-Essen Klinik f...

The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using (124)I PET(/CT) imaging.

Nuklearmedizin — Mon, 12 Jul 2010 23:00:00 +0100

CONCLUSION: The (124)I PET(/CT) salivary gland dosimetry indicated that lemon juice stimulation shortly after (131)I administration in radioiodine therapy increases the absorbed doses to the salivary glands. PMID: 20625723 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

[Outcomes of long-term combined treatment in follicular thyroid carcinoma]

Medicina (Kaunas) — Sat, 26 Jun 2010 15:39:03 +0100

Excellent Prognosis of Patients with Solitary T1N0M0 Papillary Thyroid Carcinoma who Underwent Thyroidectomy and Elective Lymph Node Dissection Without Radioiodine Therapy: Letter to the Editor

World Journal of Surgery — Thu, 17 Jun 2010 11:24:51 +0100

Content Type Journal ArticleDOI 10.1007/s00268-010-0675-1Authors Paolo Carcoforo, University of Ferrara Section of Chirurgia Generale, Department of Surgical Anaesthesiological and Radiological Sciences Ferrara ItalyDavide Sortini, Santa Maria Maddalena Private Hospital Section of Surgery Via Gorizia 2 45030 Occhiobello ItalyViola Zulian, University of Ferrara Section of Chirurgia Generale, Department of Surgical Anaesthesiological and Radiological Sciences Ferrara ItalyAnnabella Blotta, S. Orsola-Malpighi Hospital Unit of Radiotherapy, Department of Radiology Bologna ItalyRoberta Rossi, University of Ferrara Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapy Ferrara ItalyLuciano M. Feggi, Sant’Anna Hospital Nuclear Medicine Unit, Department of Diagnosti...

MedWorm Sponsor Message: Find the best January Sales in the UK.

[Nuclear medical inpatient treatment in Germany - analysis of structured quality reports 2004-2008]

Nuklearmedizin — Mon, 14 Jun 2010 10:00:03 +0100

Conclusions: In analogy to the observations from Europe after introduction of an iodine prophylaxis the improved iodine supply in Germany has led to a decline of the radioiodine therapy due to hyperthyroidism. PMID: 20198278 [PubMed - indexed for MEDLINE] (Source: Nuklearmedizin)

Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Nodular Goiter Allows Major Reduction of the Radiation Burden with Retained Efficacy.

The Journal of Clinical Endocrinology and Metabolism — Tue, 01 Jun 2010 23:00:00 +0100

Conclusions: This is the first study to demonstrate that rhTSH not only increases the thyroid (131)I uptake, but per se potentiates the effect of (131)I-therapy, allowing a major reduction of the (131)I-activity without compromising efficacy. This approach is attractive in terms of minimizing posttherapeutic restrictions and in reducing the potential risk of radiation-induced malignancy. PMID: 20519346 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Radioiodine Therapy in Differentiated Thyroid Cancer: a Nuclear Medicine Perspective

Clinical Oncology — Mon, 31 May 2010 23:00:00 +0100

The first reports of radionuclide therapy for thyroid disease used 130I, but 131I rapidly became the favoured radionuclide with beta- and gamma-ray emissions and a half-life suitable for therapy . Although thyrotoxicosis was the initial indication for 131I therapy, reports on its use in the treatment of differentiated thyroid cancer (DTC) soon followed. (Source: Clinical Oncology)

Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer

Clinical Oncology — Sun, 30 May 2010 23:00:00 +0100

Abstract: The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial. (Source: Clinical Oncology)

Medical Treatment of Hyperthyroidism: State of the Art

Experimental and Clinical Endocrinology and Diabetes — Sat, 22 May 2010 13:11:08 +0100

Exp Clin Endocrinol DiabetesDOI: 10.1055/s-0030-1253420AbstractMethimazole (MMI) and propylthiouracil (PTU) are the main antithyroid drugs used for hyperthyroidism. They inhibit the synthesis of thyroid hormone at various levels and are used as the primary treatment for hyperthyroidism or as a preparation before radioiodine therapy or thyroidectomy. MMI is the drug of choice because of its widespread availability, longer half-life and small number of severe side effects. Drugs of second choice are potassium perchlorate, beta blockers, iodine, lithium carbonate and glucocorticoids. Rituximab, a monoclonal antibody directed against human CD20, was recently proposed as a biological therapy for cases of Graves’ disease unresponsive to traditional drugs.[...]© J. A. Barth Verlag in Georg...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Salivary Gland Malignancy and Radioiodine Therapy for Thyroid Cancer

Thyroid — Sun, 16 May 2010 19:30:20 +0100

Thyroid , Vol. 0, No. 0. (Source: Thyroid)

Investigation of biokinetics of radioiodine with a population kinetics approach

Radiation Protection Dosimetry — Mon, 10 May 2010 09:09:56 +0100

The dosimetric studies required for planning individually tailored radioiodine therapy of benign thyroid pathologies may be too complex and time-demanding for many ordinary nuclear medicine departments. In this work, a preliminary population kinetics approach was applied to a model structure for iodine biokinetics in order to identify those model features that actually need to be individually investigated, in order to simplify the protocol for data collection in patients. Data from 29 patients undergoing radioiodine therapy for the treatment of the autonomous nodule syndrome were used in the analysis. The greatest inter-individual variations were observed in the parameters describing the transformation of iodide into organic iodine in the thyroid and in the kinetics of the organic form. (S...

Association between radioiodine therapy for Graves’ hyperthyroidism and thyroid-associated ophthalmopathy

International Ophthalmology — Tue, 20 Apr 2010 10:55:59 +0100

In this study, RAI therapy for Graves’ disease did not increase the risk of progression or development of ophthalmopathy in patients with mild or no eye disease at baseline. Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10792-010-9368-xAuthors Samer El-Kaissi, The University of Melbourne Department of Clinical & Biomedical Sciences, Barwon Health Ryrie Street PO Box 281 Geelong VIC 3220 AustraliaJoanne Bowden, The University of Melbourne Department of Clinical & Biomedical Sciences, Barwon Health Ryrie Street PO Box 281 Geelong VIC 3220 AustraliaMargaret J. Henry, The University of Melbourne Department of Clinical & Biomedical Sciences, Barwon Health Ryrie Street PO Box 281 Geelong VIC 3220 AustraliaMyra Yeo, The University of Melbourne Department of Clinical & ...

Fractionated Radioiodine Therapy for Hyperthyroidism Caused by Widespread Metastatic Follicular Thyroid Carcinoma

Thyroid — Mon, 12 Apr 2010 19:29:34 +0100

Thyroid , Vol. 0, No. 0. (Source: Thyroid)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Effects of drugs on the efficacy of radioiodine (131I) therapy in hyperthyroid patients

Articles of Archives of Medical Science - TERMEDIA publishing house — Tue, 09 Mar 2010 16:04:44 +0100

The treatment of hyperthyroidism is targeted at reducing the production of thyroid hormones by inhibiting their synthesis or suppressing their release, as well as by controlling their influence on peripheral tissue (conservative therapy, medical treatment). Radical treatment includes surgical intervention to reduce the volume of thyroid tissue or damage of the mechanisms of thyroid hormone synthesis by radioiodine (131I) administration. Radioiodine ( 131I) is a reactor radionuclide, produced as a result of uranium decomposition and emission of β and γ radiation. The therapeutic effects of the isotope are obtained by the emission of β radiation. In the paper, the effects of administered drugs (antithyroid, glucocorticosteroids, lithium carbonate, inorganic iodine, β-bloc...

Pulmonary Fibrosis Following Radioiodine Therapy of Pulmonary Metastases from Differentiated Thyroid Carcinoma

Thyroid — Mon, 01 Mar 2010 04:53:36 +0100

Thyroid Mar 2010, Vol. 20, No. 3: 337-340. (Source: Thyroid)

Approach to the thyroid cancer patient with extracervical metastases.

The Journal of Clinical Endocrinology and Metabolism — Mon, 01 Mar 2010 00:00:00 +0100

Authors: Haugen BR, Kane MA Patients with distant, or extracervical, metastases from differentiated thyroid cancer require multimodality diagnostic, therapeutic, and monitoring approaches. Whereas cure is the initial goal, especially in those with small, radioiodine-avid pulmonary metastases, improved survival and management of symptoms become the primary objective in many patients with persistent disease, especially those with bone metastases. Levothyroxine therapy with suppression of serum TSH is a primary therapy in all patients with advanced differentiated thyroid cancer, and this therapy has been shown to improve overall survival and slow disease progression. Radioiodine is also an important systemic therapy for those patients with radioiodine-avid disease who respond to this targ...

[Nuclear medical inpatient treatment in Germany. Analysis of the structured quality reports 2004 to 2008.]

Nuklearmedizin — Mon, 01 Mar 2010 00:00:00 +0100

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging — Thu, 25 Feb 2010 20:27:20 +0100

Content Type Journal ArticleCategory Focus onDOI 10.1007/s00259-010-1398-0Authors Massimo Salvatori, Catholic University of Sacred Heart Nuclear Medicine Institute, Policlinico Universitario “A.Gemelli” Rome ItalyMarkus Luster, University of Ulm Department of Nuclear Medicine Ulm Germany Journal European Journal of Nuclear Medicine and Molecular ImagingOnline ISSN 1619-7089Print ISSN 1619-7070 (Source: European Journal of Nuclear Medicine and Molecular Imaging)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Update on Recent Developments in the Therapy of Differentiated Thyroid Cancer

Seminars in Nuclear Medicine — Fri, 29 Jan 2010 15:14:19 +0100

This article deals with the current options of optimal therapy regimens in differentiated thyroid carcinoma. (Source: Seminars in Nuclear Medicine)

Nationwide trends in surgery and radioiodine treatment for benign thyroid disease during iodization of salt.

European Journal of Endocrinology — Mon, 18 Jan 2010 00:00:00 +0100

Conclusions: Iodization seemed to be associated with a temporary increase in the utilization rate of surgery and radioiodine therapy in the region of prior moderate ID, probably as a result of treatment of iodine-induced hyperthyroidism, but the rates ended up lower than before iodization. PMID: 20083558 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)

Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Nuklearmedizin — Wed, 13 Jan 2010 00:00:00 +0100

CONCLUSION: (124)I PET(/CT) dosimetry also corroborates the low ODpAs to the salivary glands. A voxel-based calculation taking into account the nonuniform activity distributions in the glands is necessary to possibly explain the radiation-induced salivary gland damage. PMID: 20069293 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging — Tue, 12 Jan 2010 18:17:40 +0100

Conclusion 124I PET(/CT) dosimetry also corroborates the low ODpAs to the salivary glands. A voxel-based calculation taking into account the nonuniform activity distributions in the glands is necessary to possibly explain the radiation-induced salivary gland damage. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-009-1351-2Authors Walter Jentzen, Universität Duisburg-Essen Klinik für Nuklearmedizin Hufelandstrasse 55 45122 Essen GermanyRobert F. Hobbs, Johns Hopkins University Department of Radiology, School of Medicine Baltimore MD USAAlexander Stahl, Universität Duisburg-Essen Klinik für Nuklearmedizin Hufelandstrasse 55 45122 Essen GermanyJochen Knust, Universität Duisburg-Essen Klinik für Nuklearmedizin Hufelandstrasse 55 45122 Esse...

The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment ((131)I) in hyperthyroid patients.

Endokrynologia Polska — Fri, 01 Jan 2010 00:00:00 +0100

Conclusions: The present results indicate the necessity of careful analysis of administered drugs in hyperthyroid patients while qualifying them to (131)I therapy. The initial concentration of TSH has no effect on the efficacy of radioiodine therapy in cases where absorbed doses are regarded to be ablative. (Pol J Endocrinol 2010; 61 (1): 56-61). PMID: 20205105 [PubMed - in process] (Source: Endokrynologia Polska)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Excellent Prognosis of Patients with Solitary T1N0M0 Papillary Thyroid Carcinoma Who Underwent Thyroidectomy and Elective Lymph Node Dissection Without Radioiodine Therapy

World Journal of Surgery — Wed, 30 Dec 2009 06:52:58 +0100

Conclusions These findings suggest that solitary T1N0M0 patients have an excellent prognosis when they undergo thyroidectomy and elective lymph node dissection without radioiodine therapy. Regarding the extent of thyroidectomy, hemithyroidectomy is adequate for these patients, if a 1% risk of recurrence to the remnant thyroid is accepted. Content Type Journal ArticleDOI 10.1007/s00268-009-0356-0Authors Yasuhiro Ito, Kuma Hospital Department of Surgery 8-2-35, Shimoyamate-dori, Chuo-ku Kobe City 650-0011 JapanHiroo Masuoka, Kuma Hospital Department of Surgery 8-2-35, Shimoyamate-dori, Chuo-ku Kobe City 650-0011 JapanMitsuhiro Fukushima, Kuma Hospital Department of Surgery 8-2-35, Shimoyamate-dori, Chuo-ku Kobe City 650-0011 JapanHiroyuki Inoue, Kuma Hospital Department...

Effects and safety of iopanoic acid in cats

Advances in Small Animal Medicine and Surgery — Tue, 01 Dec 2009 00:00:00 +0100

Methimazole blocks the synthesis of thyroid hormones and is the mainstay of medical treatment for hyperthyroidism in cats. However, adverse effects occur in up to 18% of treated cats. The most common adverse effects are vomiting and anorexia, but more serious effects, such as facial excoriation, hepatotoxicity, and blood dyscrasias, occur in up to 10% of cases, requiring the discontinuation of the drug. Thyroidectomy or radioiodine therapy are the usual remaining options for cats. (Source: Advances in Small Animal Medicine and Surgery)

Long-Term Outcome of Differentiated Thyroid Carcinoma: Experience in a Developing Country

World Journal of Surgery — Sun, 29 Nov 2009 09:38:23 +0100

Conclusions Advance stage at presentation and proportionately high rates of FTC and PDTC contribute to poor outcome of DTC in developing countries. Despite dismal outcome, total thyroidectomy seems to prevent thyroid bed recurrence in surviving patients. Content Type Journal ArticleDOI 10.1007/s00268-009-0293-yAuthors Panchagan Rama Kant Bhargav, Sanjay Gandhi Postgraduate Institute of Medical Sciences Department of Endocrine Surgery Raebareli Road Lucknow 226 014 IndiaAnjali Mishra, Sanjay Gandhi Postgraduate Institute of Medical Sciences Department of Endocrine Surgery Raebareli Road Lucknow 226 014 IndiaGaurav Agarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences Department of Endocrine Surgery Raebareli Road Lucknow 226 014 IndiaAmit Agarwal, Sanjay Gan...

Radioiodine concentration by the thymus in differentiated thyroid carcinoma: report of five cases

Arquivos Brasileiros de Endocrinologia e Metabologia — Fri, 27 Nov 2009 14:12:00 +0100

The radioactive iodine has been used with great value as a diagnostic and therapeutic method in patients with differentiated thyroid carcinoma previously submitted to total thyroidectomy. False-positive whole-body scans may occur due to misinterpretation of the physiologic distribution of the radioisotope or lack of knowledge on the existence of other pathologies that could eventually present radioiodine uptake. Thymic uptake is an uncommon cause of false-positive whole-body scan, and the mechanism through which it occurs is not completely understood. The present paper reports five cases of patients with differentiated thyroid cancer who presented a mediastinum uptake of radioiodine in a whole-body scan during follow-up. The patients had either histological or radiological confirmation of ...

Targeted therapies in thyroid cancer

Targeted Oncology — Tue, 10 Nov 2009 18:08:28 +0100

Abstract Differentiated thyroid carcinoma is the most frequent neoplasm of the endocrine system. Although thyroid cancer usually has an excellent prognosis, no therapeutic options are available for patients that develop metastases and are or became resistant to radioiodine therapy. The deeper knowledge of molecular aberrations that characterize tumor growth has provided novel targets in cancer therapy. Several proteins have been implicated as having a crucial role in the carcinogenesis of differentiated thyroid cancer, such as those involved in RET/PTC-RAS-RAF-MAPK pathway. Moreover, vascular aberrations and angiogenesis equilibrium have also been related to tumor growth. The development of new, targeted therapies and their encouraging initial results have opened a hopeful...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Radioiodine, Smoking Linked to Eye Disease in Graves' Hyperthyroidism

Medscape Pharmacist Headlines — Mon, 09 Nov 2009 16:57:34 +0100

Radioiodine therapy and smoking increase the risk of developing thyroid-associated ophthalmopathy in patients with Graves' hyperthyroidism, say researchers from Sweden in the October issue of The Journal of Clinical Endocrinology & Metabolism. Reuters Health Information (Source: Medscape Pharmacist Headlines)

Outcome After High-Dose Radioiodine Therapy for Advanced Differentiated Thyroid Carcinoma in Childhood

Endocrine Research — Sun, 01 Nov 2009 00:00:00 +0100

(Source: Endocrine Research)

Takotsubo cardiomyopathy following radioiodine therapy for toxic multinodular goitre.

The Netherlands Journal of Medicine — Sun, 01 Nov 2009 00:00:00 +0100

We report on a 73-year-old man with a toxic multinodular goitre, which was treated with radioiodine therapy (I-131) without pretreatment with an antithyroid drug. Four weeks later he presented with rapidly progressive dyspnoea and a significant increase in free thyroxin. The electrocardiogram showed ST -segment elevation, and echocardiography demonstrated apical akinesia and a left ventricular ejection fraction of only 25%. However, direct coronary catheterisation showed no evidence of coronary artery disease. Left ventricular angiography showed apical ballooning consistent with the diagnosis of takotsubo cardiomyopathy. Following treatment of the cardiomyopathy and thyrotoxicosis, he experienced a complete recovery. To the best of our knowledge, this is the first report of a takotsubo car...

A case of thyroid storm following radioiodine therapy underlying usefulness of cardiac MRI.

European Journal of Internal Medicine — Wed, 30 Sep 2009 18:05:40 +0100

Authors: Thebault C, Leurent G, Potier J, Bedossa M, Bonnet F PMID: 19782905 [PubMed - in process] (Source: European Journal of Internal Medicine)

Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene.

Clinical Cancer Research — Mon, 28 Sep 2009 23:00:00 +0100

CONCLUSIONS: In conclusion, our data clearly show the high potential of novel pseudodendritic polymers for tumor-specific NIS gene delivery after systemic application, opening the prospect of targeted NIS-mediated radionuclide therapy of nonthyroidal tumors even in metastatic disease. (Clin Cancer Res 2009;15(19):6079-86). PMID: 19789324 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

MedWorm Sponsor Message: Find the best January Sales in the UK.

[Subjective perception of radioactivity - no change post successful treatment with radioiodine]

Nuklearmedizin — Sat, 19 Sep 2009 12:38:06 +0100

CONCLUSION: Patients continue to view radioactivity as something negative despite treatment success following radioiodine therapy. Our results provide useful information for patient information by the nuclear medicine physician prior to a radioiodine therapy. PMID: 19322502 [PubMed - indexed for MEDLINE] (Source: Nuklearmedizin)

A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging — Thu, 17 Sep 2009 11:55:30 +0100

Conclusions A successful ablation is strongly dependent on the absorbed dose to the thyroid remnant. Dosimetry-based personalized treatment can prevent both sub-optimal administrations, which entails further radioiodine therapy, and excessive administration of radioactivity, which increases the potential for radiation toxicity. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-009-1261-3Authors Glenn D. Flux, Royal Marsden NHS Foundation Trust Department of Physics Downs Road Sutton Surrey SM2 5PT UKMasud Haq, Royal Marsden NHS Foundation Trust Thyroid Unit Downs Road Sutton Surrey SM2 5PT UKSarah J. Chittenden, Royal Marsden NHS Foundation Trust Department of Physics Downs Road Sutton Surrey SM2 5PT UKSusan Buckley, Royal Marsden NHS Foundation ...

Goitre and thyroid cancer

Medicine — Fri, 31 Jul 2009 11:53:28 +0100

Abstract: Thyroid enlargement is common and thyroid malignancy rare, but the clinical presentation of benign and malignant disease are similar. The aim of clinical assessment and investigations is to identify the small number of cancers amongst the non-malignant thyroid enlargements. Investigations include thyroid function tests and fine-needle aspiration cytology. Benign thyroid disease needs treatment only in the presence of dysfunction or local compressive symptoms. The treatment of thyroid cancer is multidisciplinary and includes surgery, radioiodine therapy and lifelong thyroid-stimulating hormone suppression. The diagnosis and management of thyroid cancer is being centralized around the multidisciplinary team in order to improve the outcomes in the UK. (Source: Medicine)

Construction of a MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for gene therapy of breast cancer

Breast Cancer Research — Sun, 26 Jul 2009 23:00:00 +0100

Conclusions: This construct may allow multimodal therapy, combining virotherapy with radioiodine therapy to be developed as a novel treatment for breast and other MUC1 overexpressing cancers. (Source: Breast Cancer Research)

Radiofrequency Ablation for the Treatment of Autonomously Functioning Thyroid Nodules

World Journal of Surgery — Mon, 06 Jul 2009 16:52:55 +0100

Conclusions RFA seems to be effective and safe for the treatment of AFTN. Content Type Journal ArticleDOI 10.1007/s00268-009-0130-3Authors Jung Hwan Baek, Thyroid Center, Daerim St. Mary’s Hospital Department of Radiology #978-13 Daerim-dong, Youngdeunpo-gu Seoul 150-070 KoreaWon-Jin Moon, Konkuk University Hospital, Konkuk University School of Medicine Department of Radiology 4-12 Hwayang-dong, Gwangjin-ku Seoul 143-729 KoreaYoon Suk Kim, Thyroid Center, Daerim St. Mary’s Hospital Department of Radiology #978-13 Daerim-dong, Youngdeunpo-gu Seoul 150-070 KoreaJeong Hyun Lee, University of Ulsan College of Medicine Department of Radiology Asan Medical Center, #388-1 Poongnap-2dong, Songpa-gu Seoul 138-736 KoreaDucky Lee, Thyroid Center, Daerim St. Mary’s Hospital D...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Radioiodine therapy of differentiated thyroid cancer: radiologic impact of out-patient treatment with 100 to 150 mCi Iodine-131 activities

Arquivos Brasileiros de Endocrinologia e Metabologia — Sun, 05 Jul 2009 10:55:22 +0100

CONCLUSIONS: No radiological impact was detected after iodine therapy with 100-150 mCi on an out-patient basis followed by experienced professionals. (Source: Arquivos Brasileiros de Endocrinologia e Metabologia)

Endogenous expression of the sodium iodide symporter mediates uptake of iodide in murine models of colorectal carcinoma

International Journal of Cancer — Mon, 29 Jun 2009 23:00:00 +0100

The sodium iodide symporter (NIS) mediates iodide uptake into the thyroid. Because of this mechanism, differentiated thyroid cancer is susceptible for radioiodine therapy. Functional NIS expression in extrathyroidal tumors has been reported mainly in breast cancer. We screened colorectal tumors for NIS expression and investigated the mechanisms regulating NIS activity. Cell lines were screened for iodide uptake in vitro and NIS expression was evaluated by real-time RT-PCR, immunocytochemistry and immunoblotting. Iodide and pertechnetate uptake were evaluated in allograft tumors by biodistribution studies and scintigraphy. Tumors of transgenic mouse models for colorectal cancer harboring mutations in the oncogenes KRAS, [beta]-catenin or the tumor-suppressor gene adenomatous-polyposis coli ...

Changing trends in the treatment of Graves' disease with radioiodine: a 12-year experience in a university hospital

Radiologia Brasileira — Thu, 25 Jun 2009 08:18:15 +0100

CONCLUSION: Radioiodine therapy has increasingly been accepted for treatment of patients with Graves' disease and the doses delivered have increased to achieve a permanent cure as well as a reduction of the chances of recurrence. (Source: Radiologia Brasileira)

Subjective perceptions of patients undergoing radioiodine therapy: why should we know about them?

European Journal of Nuclear Medicine and Molecular Imaging — Sat, 13 Jun 2009 08:37:43 +0100

Content Type Journal ArticleCategory EditorialDOI 10.1007/s00259-009-1188-8Authors Lutz S. Freudenberg, Universitätsklinikum Essen Klinik für Nuklearmedizin Hufelandstraße 55 45122 Essen GermanyStefan P. Müller, Universitätsklinikum Essen Klinik für Nuklearmedizin Hufelandstraße 55 45122 Essen GermanyAndreas Bockisch, Universitätsklinikum Essen Klinik für Nuklearmedizin Hufelandstraße 55 45122 Essen Germany Journal European Journal of Nuclear Medicine and Molecular ImagingOnline ISSN 1619-7089Print ISSN 1619-7070 (Source: European Journal of Nuclear Medicine and Molecular Imaging)

What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)?

Oncology (Williston Park, N.Y.) — Sun, 31 May 2009 23:00:00 +0100

Authors: Mazzaferri EL The incidence of papillary thyroid cancer has been rising steadily over the past 3 decades. Most tumors in this setting are regarded as low risk, but recurrence rates are high, producing controversy about initial therapy. Microcarcinomas smaller than 1 cm are generally best treated with lobectomy alone. Total thyroidectomy should be performed for tumors 1 cm or larger or for tumors that have metastasized. Prophylactic central and lateral neck lymph node compartment dissection uncovers unsuspected metastases in about half the patients, which may alleviate the need for postsurgical radioiodine therapy but can be associated with surgical complications. Radioiodine may diminish tumor recurrence but is complicated by injury to nonthyroidal tissues and by dose-related ...

Synchronous papillary carcinoma in thyroglossal duct cyst and thyroid gland: Case report and review of literature

Head — Wed, 01 Apr 2009 04:00:00 +0100

We report a rare case of synchronous occurrence of thyroglossal duct cyst carcinoma and thyroid carcinoma and discuss its management in detail.A 59-year-old woman was clinically diagnosed to have a thyroglossal duct cyst and a solitary nodule. Fine-needle aspiration cytology revealed a papillary carcinoma in the thyroglossal duct cyst and a colloid in the thyroid nodule. Sistrunk's procedure along with a total thyroidectomy was performed followed by postoperative radioiodine ablation.Histopathologic examination revealed thyroglossal duct cyst carcinoma and bilateral foci of papillary carcinoma in the thyroid gland. She has remained free of disease on follow-up.Most cancers arising in thyroglossal duct cysts are of low risk, and Sistrunk's procedure is an adequate treatment for such cancers...

The relationship between 24 h/4 h radioiodine-131 uptake ratio and outcome after radioiodine therapy in 1402 patients with solitary autonomously functioning thyroid nodules

Annals of Nuclear Medicine — Thu, 26 Mar 2009 08:25:48 +0100

Conclusions The 131I UR can predict the outcome of 131I treatment in AFTN and may have utility in modifying treatment in some patients to limit post-radioiodine induced hypothyroidism and treatment failures in order to achieve euthyroidism. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s12149-009-0232-xAuthors Mauro Filesi, ‘La Sapienza’ University Department of Clinical Sciences, Nuclear Medicine, Policlinico Umberto I Viale del Policlinico 155 00161 Rome ItalyLaura Travascio, ‘La Sapienza’ University Department of Clinical Sciences, Nuclear Medicine, Policlinico Umberto I Viale del Policlinico 155 00161 Rome ItalyTeresa Montesano, ‘La Sapienza’ University Department of Clinical Sciences, Nuclear Medicine, Policlinico Umberto I Viale del...

[HEAD & NECK] The Role of MR Imaging in Detecting Nodal Disease in Thyroidectomy Patients with Rising Thyroglobulin Levels

American Journal of Neuroradiology — Wed, 11 Mar 2009 04:00:00 +0100

CONCLUSIONS: MR imaging of the neck should be considered in thyroidectomy patients with rising serum thyroglobulin levels and a history of radioiodine therapy and neck dissection. Radiologists should carefully examine the retropharyngeal and parapharyngeal spaces in these patients because nodal metastases may occur there more commonly than realized. (Source: American Journal of Neuroradiology)

A novel view on dosimetry-related radionuclide therapy: Presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging — Fri, 27 Feb 2009 13:51:41 +0100

Conclusion Redistribution of therapeutic activities along the model, i.e. taking into account success and risk, may enhance response while on average saving activity as exemplarily shown by a virtual comparison with standard approaches using literature data from DTC for implementation. The model may thus provide a guideline for the prescription of therapeutic activities; the results underline the potential impact of individual dosimetry in radionuclide therapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-009-1077-1Authors Alexander R. Stahl, University of Duisburg-Essen Clinic for Nuclear Medicine Hufelandstr. 55 45122 Essen GermanyLutz Freudenberg, University of Duisburg-Essen Clinic for Nuclear Medicine Hufelandstr. 55 45122 Essen German...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Radioiodine Therapy for Thyroid Cancer Depicted Uterine Leiomyoma.

Clinical Nuclear Medicine — Fri, 20 Feb 2009 18:36:55 +0100

Page: 180DOI: 10.1097/RLU.0b013e3181966ff0Authors: Hirata, Kenji MD *; Shiga, Tohru MD, PhD *; Kubota, Kanako C. MD +; Okamoto, Shozo MD *; Kamibayashi, Tomohito MD *; Tamaki, Nagara MD, PhD * (Source: Clinical Nuclear Medicine)

Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy.

Current Pharmaceutical Design — Wed, 21 Jan 2009 07:29:20 +0100

This article is going to show that molecular imaging probes in Nuclear Medicine can be regarded as proof of principle of many of recent trends in diagnosis and therapy and offers exciting opportunities for further developments. Radioiodine therapy of benign and malignant thyroid disease has been established in Nuclear Medicine over six decades ago and is a fine example for using the same highly specific probe for diagnosis and treatment of a given disease. The use of radio labeled monoclonal antibodies against surface receptors of tumor cells (e.g. CEA) dominated diagnostic Nuclear Medicine in the eighties and sees a recent revival in lymphoma treatment radioimmunotherapy. Finally Nuclear Medicine has shown that it may advance drug development by visualizing its biodistribution and site of...

Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines

European Journal of Nuclear Medicine and Molecular Imaging — Wed, 24 Dec 2008 08:51:11 +0100

Conclusion We hypothesize that testing of cells from primary tumours or metastases in patients may be a way to identify compounds with optimum therapeutic efficacy for individualized treatment. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-008-1024-6Authors Eleonore Fröhlich, University of Tuebingen Department of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, Internal Medicine Otfried-Muellerstrasse 10 72076 Tuebingen GermanyPeter Brossart, University of Tuebingen Department of Haematology, Oncology, Immunology and Rheumatology, Internal Medicine Otfried-Muellerstrasse 10 72076 Tuebingen GermanyRichard Wahl, University of Tuebingen Department of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, Internal Medicine Otf...

Radioiodine Therapy (RAI) for Graves' Disease (GD) and the Effect on Ophthalmopathy: A Systematic Review

Medscape Radiology Headlines — Tue, 23 Dec 2008 21:29:03 +0100

Does radioiodine therapy for Graves' disease, antithyroid drugs, or surgery raise the risk of ophthalmopathy? Does glucocorticoid prophylaxis effectively prevent ophthalmopathy occurrence/progression? Clinical Endocrinology (Source: Medscape Radiology Headlines)

Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.

European Journal of Clinical Investigation — Sat, 20 Dec 2008 08:23:27 +0100

Conclusions Simultaneous carbimazole reduces the euthyroidism rate, the aim of low-dose radioiodine therapy, over the entire target dose range in both Graves' disease and toxic nodular goitre. Therefore, antithyroid drug discontinuation should be preferred in low-dose radioiodine therapy. Conversely, escalation of the target dose should be preferred in high-dose radioiodine therapy. PMID: 19087129 [PubMed - in process] (Source: European Journal of Clinical Investigation)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance.

Nuklearmedizin — Sun, 07 Dec 2008 08:14:01 +0100

CONCLUSIONS: Relative uptake of subsequent radioiodine fractions decreases with time after first administration and with increasing delivered dose to the thyroid. If a second fraction of (131)I is given at an earlier time, the same therapeutic effect can be reached using lower amounts of activity, minimising radiation exposure and increasing efficiency of radioiodine therapy. PMID: 19057798 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

[Salivary gland damage after (131)I therapy in patient with differentiated thyroid cancer. Preliminary report.]

Endokrynologia Polska — Mon, 01 Dec 2008 16:15:09 +0100

Conclusions: The main conclusion is that a single dose of (131)I has no significant influence on salivary gland function; a repeated high-doses therapy is connected with an essential risk of side-effect occurrence. Scintigraphy can evaluate salivary gland function with high sensitivity. Parotid glands are more radiosensitive than submandibular. (Pol J Endocrinol 2008; 59 (5): 403-410). PMID: 18979451 [PubMed - as supplied by publisher] (Source: Endokrynologia Polska)

Diagnostic Whole-Body Scanning Before Radioiodine Therapy for Pulmonary Metastases of Differentiated Thyroid Cancer: Predictive Value and Recommendations.

Clinical Nuclear Medicine — Fri, 21 Nov 2008 08:14:41 +0100

Page: 845DOI: 10.1097/RLU.0b013e31818bf146Authors: Tachi, Yasushi MD *; Iwano, Shingo MD *; Kato, Katsuhiko MD *; Tadokoro, Masanori MD +; Naganawa, Shinji MD * (Source: Clinical Nuclear Medicine)

[Nuclear Medicine and Molecular Imaging] Incremental Value of Diagnostic 131I SPECT/CT Fusion Imaging in the Evaluation of Differentiated Thyroid Carcinoma

American Journal of Roentgenology — Wed, 19 Nov 2008 05:00:00 +0100

CONCLUSION. Iodine-131 SPECT/CT is useful for accurate evaluation of regional and distant activity in characterization of foci as residual thyroid tissue or nodal, pulmonary, or osseous metastasis. Suspected physiologic mimics of disease can be confirmed with increased reader confidence. (Source: American Journal of Roentgenology)

Thyroid cancer in infants and adolescents after Chernobyl.

Nuklearmedizin — Sat, 18 Oct 2008 09:56:59 +0100

Authors: Reiners C, Demidchik YE, Drozd VM, Biko J Studies in children medically exposed to external irradiation more than 50 years ago revealed a considerably increased risk for thyroid cancer. Similarly, a strongly age-dependent risk for thyroid cancer was observed in the Japanese population after the atomic bomb explosions with the highest risk in the group of children below age of 10. After the Chernobyl accident, children from Belarus living in highly exposed regions received mean thyroid doses by radioactive fallout higher by a factor of approximately 2 as compared to the survivors of the atomic bomb explosions. This lead to a radiation related increase of thyroid cancer incidence in children and adolescents with the highest incidence in age group 0-4 years up to now totally amou...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions.

Clinical Endocrinology — Wed, 10 Sep 2008 04:00:00 +0100

Authors: Tanda ML, Lai A, Bartalena L PMID: 18785990 [PubMed - as supplied by publisher] (Source: Clinical Endocrinology)

Guidelines for radioiodine therapy of differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging — Fri, 01 Aug 2008 06:09:52 +0100

Discussion For this purpose, recommendations have been formulated based on recent literature and expert opinion regarding the rationale, indications and contraindications for these procedures, as well as the radioiodine activities and the administration and patient preparation techniques to be used. Recommendations also are provided on pre-RAIT history and examinations, patient counselling and precautions that should be associated with 131I iodine ablation and treatment. Furthermore, potential side effects of radioiodine therapy and alternate or additional treatments to this modality are reviewed. Appendices furnish information on dosimetry and post-therapy scintigraphy. Content Type Journal ArticleCategory GuidelinesDOI 10.1007/s00259-008-0883-1Authors M. Luster, U...

Recombinant human thyrotropin stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration.

The Journal of Clinical Endocrinology and Metabolism — Tue, 29 Jul 2008 04:00:00 +0100

Conclusion: On average, neither compression of the trachea nor deterioration of the pulmonary function was observed in the acute phase following rhTSH-augmented (131)I therapy. In the long term tracheal compression is diminished, and the inspiratory capacity improved, compared with (131)I therapy alone. PMID: 18664541 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Conventional withdrawal of thyroid hormone before radioiodine therapy in differentiated thyroid carcinoma: how frequently are adequately raised TSH levels attained?

Clinical Endocrinology — Wed, 18 Jun 2008 02:11:21 +0100

Clinical Endocrinology, Volume 69, Issue 1, Page 169-170, July 2008. (Source: Clinical Endocrinology)

Multiple Relapses of Hyperthyroidism after Thyroid Surgeries in a Patient with Long Term Follow-up of Sporadic Non-autoimmune Hyperthyroidism

Experimental and Clinical Endocrinology and Diabetes — Fri, 06 Jun 2008 16:26:18 +0100

We report on a 22 year old male patient who was treated for his multiple relapses of hyperthyroidism by repeated subtotal thyroidectomies (STE). During the 22 years of follow-up, the patient developed several relapses of hyperthyroidism, four of them after thyroid surgeries. Sequencing of the TSHR gene revealed a gain-of-function mutation with an amino acid exchange of aspartate to tyrosine in codon 633 which is located in the sixth transmembrane domain of the TSH receptor. The absence of the mutation in all other family members identifies the patient's TSHR mutation as a sporadic germline mutation. In this patient, thyroid tissue growth and hyperthyroidism could repeatedly be controlled only for limited periods by near total thyroidectomy. Therefore, this case confirms that early combined...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Survey of management of solitary thyroid nodules in Germany.

Nuklearmedizin — Thu, 22 May 2008 14:58:40 +0100

CONCLUSIONS: The main differences of opinion between practitioners and specialists focused on calcitonin screening and referral to radioiodine therapy. PMID: 18493687 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter

Endocrine — Tue, 20 May 2008 06:10:11 +0100

Abstract Radioiodine (131I) treatment for nontoxic and toxic multinodular goiter (MNG) is an alternative therapeutic procedure used especially for patients with contraindication for surgery. Several studies have been conducted in recent years assessing the use of recombinant human TSH (rhTSH) in increasing 131I uptake in MNGs. This procedure also decreases the activity level of the administered 131I, changes the distribution of 131I in the thyroid, lowers the absorption dose, and dramatically reduces the volume of the goiter (50–75% of the baseline volume). A major disadvantage, however, is the induction of hypothyroidism in a relatively large number of patients. A transient increase in thyroid volume and tenderness was noted in the first week of treatment. Also a short pe...

Graves' Disease and Thyroid Associated Ophthalmopathy following Radioiodine Therapy in Euthyroid Multinodular Goiter

Thyroid — Thu, 08 May 2008 17:01:40 +0100

Thyroid May 2008, Vol. 18, No. 5: 585-585. (Source: Thyroid)

[Is radioiodine therapy conducted too late in patients suffering from thyroid autonomy?]

Nuklearmedizin — Wed, 07 May 2008 21:11:40 +0100

CONCLUSION: Despite clear recommendations in corresponding guidelines too much time passes between first symptoms (median: 73 months), primary diagnosis of therapy relevant thyroid autonomy (median: 2 months) and implementation of RIT. Patients with functional and/or local symptoms should be examined for thyroid autonomy early. If thyroid autonomy is proven, RIT should be planned immediately, especially in high-risk patients. PMID: 18278206 [PubMed - indexed for MEDLINE] (Source: Nuklearmedizin)

[Radioiodine therapy in thyroid autonomy: initial results and experiences.]

Orvosi Hetilap — Sat, 26 Apr 2008 21:06:02 +0100

Conclusions: The results of radioiodine therapy in the analysed patient group are coherent with the data of several large studies. According to the references, the success rate of 85-100% are satisfying and the incidence of hypothyroidism of 10-20% is acceptable. PMID: 18436512 [PubMed - in process] (Source: Orvosi Hetilap)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Does radioiodine therapy for hyperthyroidism increase long-term morbidity?

Nature Clinical Practice Endocrinology and Metabolism — Tue, 04 Mar 2008 05:00:00 +0100

Authors: Burman KD PMID: 18317480 [PubMed - as supplied by publisher] (Source: Nature Clinical Practice Endocrinology and Metabolism)

[Acute effects of radioiodine therapy on the voice and larynx of Basedow-Graves patients.]

Revista Brasileira de Otorrinolaringologia — Sat, 01 Mar 2008 05:00:00 +0100

CONCLUSION: Radioiodine therapy does not affect voice quality. PMID: 18568200 [PubMed - in process] (Source: Revista Brasileira de Otorrinolaringologia)

[Acute effects of radioiodine therapy on the voice and larynx of Basedow-Graves patients]

Revista Brasileira de Otorrinolaringologia — Sat, 01 Mar 2008 05:00:00 +0100

CONCLUSION: Radioiodine therapy does not affect voice quality. PMID: 18568200 [PubMed - in process] (Source: Revista Brasileira de Otorrinolaringologia)

[Influence of the endogene TSH stimulation of thyroid volume increase in the patients after total thyroidectomy due to differentiated thyroid cancer]

Endokrynologia Polska — Sat, 01 Mar 2008 05:00:00 +0100

CONCLUSIONS: L-Thyroxine withdrawal in the patients after total thyroidectomy due to DTC can cause re-growth of the tissue remnants. The phenomenon may be of a clinical significance in the selected cases influencing therapeutic decisions. PMID: 18465686 [PubMed - indexed for MEDLINE] (Source: Endokrynologia Polska)

Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?

Nuklearmedizin — Tue, 19 Feb 2008 20:43:20 +0100

CONCLUSION: To achieve a dose of over 200 Gy with the above standard deviation, we recommend calculating an intended dose of 250 Gy and using a dosimetric approach with early and late uptake values in the radioiodine test, to allow early therapeutic intervention should the posttherapeutic thyroid dose fall unexpectedly below 200 Gy. PMID: 18278207 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Is radioiodine therapy conducted too late in patients suffering from thyroid autonomy?

Nuklearmedizin — Tue, 19 Feb 2008 20:43:20 +0100

The carcinogenic effects of radioiodine therapy for thyroid carcinoma.

Nature Clinical Practice Endocrinology and Metabolism — Tue, 19 Feb 2008 05:00:00 +0100

Authors: de Vathaire F PMID: 18283326 [PubMed - as supplied by publisher] (Source: Nature Clinical Practice Endocrinology and Metabolism)

Decreased radioiodine uptake of FRTL-5 cells after 131I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway

European Journal of Nuclear Medicine and Molecular Imaging — Tue, 29 Jan 2008 15:47:31 +0100

Conclusions It could be demonstrated that during 131I incubation of FRTL-5 cells, radioiodine uptake decreased significantly. Simultaneously decreasing levels of NIS mRNA and protein expression suggest a NIS-associated mechanism. Since mRNA levels of housekeeping genes decreased, too, the reduced NIS expression might be provoked by a cell cycle arrest. Our investigations recommend the FRTL-5 model as a valuable tool for further molecular biological investigations of the stunning phenomenon. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-007-0666-0Authors Birgit Meller, University of Lübeck Clinic of Radiology and Nuclear Medicine Ratzeburger Allee 160 23538 Lübeck GermanyErzsébet Gaspar, University of Lübeck Clinic of Internal Medicine I ...

Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer

Annals of Nuclear Medicine — Wed, 21 Nov 2007 16:42:24 +0100

The objective of this study was to report three cases with an accumulation of 131I in the nasolacrimal duct after radioiodine therapy for papillary thyroid cancer. A whole-body scan was taken 3 days after the administration of 3.7 GBq of 131I. Single-photon emission computed tomography (SPECT)/CT images were added when the location of a focal tracer uptake was undetermined on whole-body scans. In case 1, a 62-year-old woman complained of epiphora of the left eye after nine radioiodine therapies with a cumulative dose of 31.08 GBq. The left nasolacrimal duct was visualized at her tenth treatment with 131I. In case 2, a series of three radioiodine therapies had been given to a 73-year-old woman with a cumulative dose of 11.1 GBq. The accumulation of 131I was noted in the left nasol...

Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer

Strahlentherapie und Onkologie — Tue, 20 Nov 2007 15:30:06 +0100

Conclusion Parenchymal damage in salivary glands induced by high-dose radioiodine treatment can be reduced significantly by amifostine. This may help to increase patients’ quality of life in differentiated thyroid cancer. Content Type Journal ArticleCategory OriginalarbeitDOI 10.1007/BF02753843Authors Karl H. Bohuslavizki, University Hospital Eppendorf Department of Nuclear Medicine Martinistra\e 52 D-20246 HamburgSusanne Klutmann, University Hospital Eppendorf Department of Nuclear Medicine Martinistra\e 52 D-20246 HamburgChristian Bleckmann, University Hospital Eppendorf Department of Nuclear Medicine Martinistra\e 52 D-20246 HamburgWinfried Brenner, Christian Albrechts University of Kiel Clinic of Nuclear Medicine GermanyStefan Lassmann, Christian Albrechts Univer...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSH

Endocrine — Sat, 17 Nov 2007 23:21:04 +0100

In conclusion, rhTSH stimulated RAI treatment of MNG did not affect structural and functional parameters of the heart, despite transient high-serum levels of thyroid hormones. Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12020-007-9020-3Authors Maria Fernanda Barca, University of Sao Paulo Medical School Thyroid Unit, Division of Endocrinology, Department of Medicine Sao Paulo 01246-000 BrazilCesar Gruppi, University of Sao Paulo Medical School Instituto do Coração (INCOR) Sao Paulo 01246-000 BrazilMucio T. Oliveira, University of Sao Paulo Medical School Instituto do Coração (INCOR) Sao Paulo 01246-000 BrazilRossana Romão, University of Sao Paulo Medical School Thyroid Unit, Division of Endocrinology, Department of Medicine Sao Paulo 01246-000 BrazilMaria Si...

Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma

Clinical Endocrinology — Wed, 07 Nov 2007 02:39:07 +0100

Clinical Endocrinology, Volume 0, Issue 0, Page ???, December 2004. Summary Objective To evaluate the effects of pretreatment with the retinoid X receptor (RXR) agonist bexarotene on the efficacy of radioiodine therapy for metastases of differentiated thyroid carcinoma (DTC) with limited uptake of radioiodine (I-131). ... (Source: Clinical Endocrinology)

[Sodium iodide symporter in physiology and diseases -- the current state of knowledge]

Endokrynologia Polska — Thu, 01 Nov 2007 04:00:00 +0100

Authors: Wolny M, Syrenicz A The sodium iodide symporter, called also the NIS protein is responsible for iodine trapping to the cell what is significant for the thyroid function. Identified and described for the first time in 1996 NIS protein is the matter of interest of investigators concerning the thyroid physiology and pathology as well as others organs which concentrate the iodine. Existing studies on the sodium iodide symporter include among others: indicating NIS protein expression in the thyroid diseases and extrathyroidal tissues, studying of the NIS antygenicity in the autoimmune diseases of thyroid, finding the molecular aspects of the difference in the NIS protein activity. The sodium iodide symporter is a base of radioiodine therapy of, as for now, thyroid diseases only. Sh...

Procedure guideline for radioiodine therapy and (131)iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer.

Nuklearmedizin — Wed, 17 Oct 2007 14:06:13 +0100

Authors: Franzius C, Dietlein M, Biermann M, Frühwald M, Linden T, Bucsky P, Reiners C, Schober O The procedure guideline for radioiodine ((131)I) therapy and (131)I whole-body scintigraphy of differentiated thyroid cancer in paediatric patients is the counterpart to the procedure guidelines (version 3) for adult patients and specify the interdisciplinary guideline for thyroid cancer of the Deutsche Krebsgesellschaft concerning the nuclear medicine part. Characteristics of thyroid cancer in children are the higher aggressiveness of papillary thyroid cancer, the higher frequency of extrathyroidal extension and of disseminated pulmonary metastases as well as the high risk of local recurrences. Radioiodine therapy is generally recommended in children, the (131)I activity depends on t...